TD Cowen Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN) had its price objective lifted by research analysts at TD Cowen from $31.00 to $32.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price target indicates a potential upside of 32.88% from the company’s previous close.

A number of other equities analysts have also commented on the company. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley increased their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners increased their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded up $0.69 during trading hours on Thursday, reaching $24.08. The company had a trading volume of 738,353 shares, compared to its average volume of 5,425,314. Elanco Animal Health has a one year low of $13.15 and a one year high of $27.72. The business has a fifty day simple moving average of $22.96 and a 200 day simple moving average of $23.49. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The firm has a market cap of $12.03 billion, a PE ratio of -48.27, a price-to-earnings-growth ratio of 1.59 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the company earned $0.37 earnings per share. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts anticipate that Elanco Animal Health will post 1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of ELAN. NewEdge Advisors LLC boosted its holdings in shares of Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares in the last quarter. Huntington National Bank boosted its holdings in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares in the last quarter. Root Financial Partners LLC boosted its holdings in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health in the 4th quarter worth about $41,000. Finally, Torren Management LLC purchased a new position in shares of Elanco Animal Health in the 4th quarter worth about $46,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.